ones insulin resist primary risk factor nonalcohol fatty liver disease named genre exhibit nonprogress simply steatosi howe signifies subset patient progress steatohepat nash define present inflamed hepatocyt injury fibrosis unfortun approve therapy therefore therapeutic approach urgent need niclosamid unit state food drug administer fdaapprov anthelmint media effect uncoupl oid phosphorus salt form ethanolamin nen piperazin npp shown efficacy marin model diet induce character attend protein phenotype improv glucose metal exact meghan under chang remain unclear bail uncoupl lead increase energy expenditure lipid ka media glucagon signal propos poor water soluble low oral bioavail admit mitochondria active potent genotox reduce enthusiasm clinic use recent demons retain suggest develop safer effect derive treatment type dialect may possible herein explore semi substitute phenylbenzamid salicylanilid chemotyp attend heat use novel phenotype vitro model high fat diet mouse studi identify compound prelim property vivo use allen symptom protect progress metal syndrome 